Sol-Gel Technologies (SLGL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sol-Gel Technologies has struck six exclusive licensing deals to market their dermatology products TWYNEO and EPSOLAY in most European countries and South Africa, with financials involving upfront and milestone payments up to low 7-digit USD figures, alongside future sales royalties. These agreements, which include commitments to minimum annual sales, build on Sol-Gel’s existing partnerships in the US, Canada, and China, showcasing the growing global confidence in their products. The company continues to advance its clinical trials for other potential treatments, further strengthening its competitive position in the dermatology pharmaceutical market.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.